BURNABY, BC, July 6 /PRNewswire-FirstCall/ - Chromos Molecular Systems Inc. today announced that Ron MacKenzie has been appointed to its Board of Directors.
“Ron brings over 25 years of biotechnology/technology experience and leadership skills to this role,” said Darrell Elliott, Chairman and Director of Chromos. “We are delighted to welcome Mr. MacKenzie to Chromos’ board of directors and look to benefit from his substantial industry experience as we guide management toward achieving our strategic goals.”
Mr. MacKenzie co-founded QLT Inc. and Inex Pharmaceuticals Inc. and served as a director and senior executive with each company during its initial years. He has also been both investor and director of a number of smaller, private companies, primarily in technology fields. He currently serves as a director of Pender NDI Life Sciences Fund (VCC) Inc. He holds a chemical engineering degree from Queen’s University and an MBA from the University of Western Ontario.
This appointment brings the number of directors on the Board to six.
Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders. The Company’s lead program, CHR-1103, is a humanized monoclonal antibody being developed as a treatment for acute relapses associated with relapsing forms of multiple sclerosis. Chromos generates revenue from its proprietary ACE System technology to engineer production quality cell lines to manufacture biopharmaceutical products including monoclonal antibodies. For more information visit our website at www.chromos.com.
Risks and Uncertainties
Certain of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Chromos (the “Company”), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
To the extent possible, management implements strategies to reduce or mitigate the risks and uncertainties associated with the Company’s operations. Operating risks include (i) the continued availability of capital to finance the Company’s activities; (ii) the Company’s limited cash position, (iii) the ability to successfully obtain proof of the effectiveness of the Company’s technology (iv) the ability to complete and maintain corporate alliances relating to the development and commercialization of the Company’s technology; (v) the ability to obtain and enforce patent and other intellectual property protection for the Company’s technology; (vi) market acceptance of the Company’s technology; (vii) the competitive environment and impact of technological change; (viii) the Company’s ability to attract and retain employees to carry out its business plans and (ix) the timely development and commercialization of any technology or products that are contingent on the completion and maintenance of corporate alliances with third parties. Further details on Chromos’ operating risks can be found in the Company’s Quarterly and Annual Reports to Shareholders.
CONTACT: Joseph Zendegui, Ph.D., Vice President, Corporate Development, Tel: (604) 415-7128, Email:jzendegui@chromos.com, Website: www.chromos.com
Chromos Molecular Systems Inc.
CONTACT: Joseph Zendegui, Ph.D., Vice President, Corporate Development,Tel: (604) 415-7128, Email:jzendegui@chromos.com, Website: www.chromos.com
